Benitec Biopharma Inc. BNTC
Set alert
8.35 USD -0.14 -1.65%
As of Nov 3, 2:29 PM ET
8.35 Day range 8.89
7.89 52-week range 15.86
- YTD
- -38.01%
- 1 year
- -47.35%
- Open
- 8.58
- Prev close
- 8.49
- Mkt cap
- 291.33M
- Vol
- 46.73K
- Avg vol
- 179.66K
- EPS
- -0.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.35
- High
- 8.89
- Forward P/E
- -1.23
- Beta
- 0.88
- Short ratio
- 1.35
- Inst. own
- 82.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 10.82
- 200-d avg
- 8.69
- 1y target
- 25.43
6M chart
Signals (31)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 4 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 2 months ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| SMA: Bullish | Jul 29, 2026 | 3 months ago |
Newest 20 of 31.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 25.43 +204.5% upside
Now 8.35
- Target (low)
- 17.00
- Target (mean)
- 25.43
- Target (high)
- 35.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 5
- 2 months ago 5
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.39 | -0.39 – -0.39 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Next quarter | -0.42 | -0.42 – -0.42 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Baird | Initiated | — | Outperform |
| Dec 3, 2024 | Guggenheim | Reiterated | Buy | Buy |
| Jul 22, 2024 | Leerink Partners | Initiated | — | Outperform |
| Jun 13, 2024 | Piper Sandler | Initiated | — | Overweight |
| Apr 22, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Feb 15, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jan 24, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Sep 26, 2023 | JMP Securities | Maintained | Market Outperform | Market Outperform |